PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
ED  - McKenney, James M.
TI  - New Monoclonal Antibody to PCSK9 Markedly Lowers LDL-C in Patients on Atorvastatin
DP  - 2012 Jun 01
TA  - MD Conference Express
PG  - 20--21
VI  - 12
IP  - 4
4099  - http://mdc.sagepub.com/content/12/4/20.short
4100  - http://mdc.sagepub.com/content/12/4/20.full
AB  - Proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) binds to low-density lipoprotein receptors (LDLRs) and plays a pivotal role in LDLR degradation [McKenney JM et al. J Am Coll Cardiol 2012]. This article discusses outcomes on the low-density lipoprotein cholesterol-lowering effects of SAR236553/REGN727 (SAR236553), a highly specific, fully human monoclonal antibody to PCSK9 [Efficacy and Safety Evaluation of SAR236553 (REGN727) In Patients With Primary Hypercholesterolemia and LDL-Cholesterol on Stable Atorvastatin Therapy; NCT01288443].